These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 36230853)

  • 1. Head-to-Head Comparison of BRAF/MEK Inhibitor Combinations Proposes Superiority of Encorafenib Plus Trametinib in Melanoma.
    Schulz A; Raetz J; Karitzky PC; Dinter L; Tietze JK; Kolbe I; Käubler T; Renner B; Beissert S; Meier F; Westphal D
    Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for
    Hamid O; Cowey CL; Offner M; Faries M; Carvajal RD
    Cancers (Basel); 2019 Oct; 11(11):. PubMed ID: 31653096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations.
    Trojaniello C; Festino L; Vanella V; Ascierto PA
    Expert Rev Clin Pharmacol; 2019 Mar; 12(3):259-266. PubMed ID: 30652516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Network indirect comparison of 3 BRAF + MEK inhibitors for the treatment of advanced BRAF mutated melanoma.
    Consoli F; Bersanelli M; Perego G; Grisanti S; Merelli B; Berruti A; Petrelli F
    Clin Transl Oncol; 2020 Jun; 22(6):900-907. PubMed ID: 31555967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
    Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
    Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B-rapidly accelerated fibrosarcoma-mutated advanced melanoma.
    Graf NP; Koelblinger P; Galliker N; Conrad S; Barysch M; Mangana J; Dummer R; Cheng PF; Goldinger SM
    J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):686-692. PubMed ID: 30468696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma.
    Kakadia S; Yarlagadda N; Awad R; Kundranda M; Niu J; Naraev B; Mina L; Dragovich T; Gimbel M; Mahmoud F
    Onco Targets Ther; 2018; 11():7095-7107. PubMed ID: 30410366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid Tumors.
    Grimaldi AM; Simeone E; Festino L; Vanella V; Strudel M; Ascierto PA
    Am J Clin Dermatol; 2017 Dec; 18(6):745-754. PubMed ID: 28537004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring the In Vitro and In Vivo Therapeutic Potential of BRAF and MEK Inhibitor Combination in NRAS-Mutated Melanoma.
    Niessner H; Hüsch A; Kosnopfel C; Meinhardt M; Westphal D; Meier F; Schilling B; Sinnberg T
    Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients.
    Daud A; Gill J; Kamra S; Chen L; Ahuja A
    J Hematol Oncol; 2017 Jan; 10(1):3. PubMed ID: 28052762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management.
    Gogas HJ; Flaherty KT; Dummer R; Ascierto PA; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Sileni VC; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Gollerkeri A; Pickard MD; Robert C
    Eur J Cancer; 2019 Sep; 119():97-106. PubMed ID: 31437754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Achievements and challenges of molecular targeted therapy in melanoma.
    Sullivan R; LoRusso P; Boerner S; Dummer R
    Am Soc Clin Oncol Educ Book; 2015; ():177-86. PubMed ID: 25993155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF and MEK Inhibitors and Their Toxicities: A Meta-Analysis.
    Garutti M; Bergnach M; Polesel J; Palmero L; Pizzichetta MA; Puglisi F
    Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of BRAF-Targeted Therapy for Advanced Melanoma in the Immunotherapy Era.
    Vanella V; Festino L; Trojaniello C; Vitale MG; Sorrentino A; Paone M; Ascierto PA
    Curr Oncol Rep; 2019 Jul; 21(9):76. PubMed ID: 31359162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment combinations in BRAF-mutant metastatic melanoma.].
    Depenni R
    Recenti Prog Med; 2021 Apr; 112(4):40e-43e. PubMed ID: 33877098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care.
    Simeone E; Grimaldi AM; Festino L; Vanella V; Palla M; Ascierto PA
    BioDrugs; 2017 Feb; 31(1):51-61. PubMed ID: 28058658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current Advances in the Treatment of BRAF-Mutant Melanoma.
    Patel H; Yacoub N; Mishra R; White A; Long Y; Alanazi S; Garrett JT
    Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32092958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma
    Tarhini AA; Toor K; Chan K; McDermott DF; Mohr P; Larkin J; Hodi FS; Lee CH; Rizzo JI; Johnson H; Moshyk A; Rao S; Kotapati S; Atkins MB
    ESMO Open; 2021 Apr; 6(2):100050. PubMed ID: 33556898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Long-term efficacy of encorafenib plus binimetinib combined treatment: case report.].
    Spagnolo F
    Recenti Prog Med; 2021 Apr; 112(4):49e-52e. PubMed ID: 33877100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.